Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Invested Capital (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Invested Capital for 16 consecutive years, with $487.9 million as the latest value for Q4 2025.

  • Quarterly Invested Capital fell 34.13% to $487.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $487.9 million through Dec 2025, down 34.13% year-over-year, with the annual reading at $487.9 million for FY2025, 34.13% down from the prior year.
  • Invested Capital for Q4 2025 was $487.9 million at Myriad Genetics, down from $492.3 million in the prior quarter.
  • The five-year high for Invested Capital was $1.0 billion in Q1 2021, with the low at $447.5 million in Q2 2025.
  • Average Invested Capital over 5 years is $803.6 million, with a median of $810.8 million recorded in 2023.
  • The sharpest move saw Invested Capital rose 6.68% in 2024, then plummeted 42.66% in 2025.
  • Over 5 years, Invested Capital stood at $967.8 million in 2021, then dropped by 8.47% to $885.8 million in 2022, then decreased by 7.24% to $821.7 million in 2023, then decreased by 9.86% to $740.7 million in 2024, then tumbled by 34.13% to $487.9 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $487.9 million, $492.3 million, and $447.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.